TIDMWDC
RNS Number : 5250V
WideCells Group PLC
31 January 2017
31 January 2017
WideCells Group PLC ('WideCells Group' or 'the Company')
Director Purchases and Grant of Options
WideCells Group PLC, the healthcare services company focused on
providing stem cell services and ground breaking insurance for stem
cell treatment, is pleased to announce that Chairman Dr. Graham
Hine, Chief Executive Officer João Andrade, Chief Financial Officer
David Bridgland, Chief Operating Officer Lopes Gil and
Non-Executive Director Marilyn Orcharton have purchased a combined
total of 100,000 new ordinary shares in the Company (the 'Director
Purchases').
Additionally, the Company announces that between December 2016
and January 2017 the Company granted options ('Options') over
380,000 ordinary shares of 0.25 pence each in the capital of the
Company ('Ordinary Shares') pursuant to the Company's EMI Share
Option Plan. The Options have been granted to employees of the
Company in recognition of their significant contribution towards
progressing WideCell's innovative stem cell services offering. The
Options are exercisable at 14 pence per Ordinary Share, being the
closing market price on 14 December 2016, with an expiry date for
exercise of 14 December 2026.
Director Purchases
Details of the Director Purchases can be found in the table
below:
Director Number of Share Number of Share Capital
Shares Purchased Purchase shares held (%) following
Price following the Director
the Director Purchase
Purchase
------------------- ------------------ ---------- -------------- ---------------
Graham Hine 20,000 13.37p 3,198,698 5.92%
------------------- ------------------ ---------- -------------- ---------------
João
Andrade 20,000 13.25p 8,020,000 14.84%
------------------- ------------------ ---------- -------------- ---------------
David Bridgland 20,000 13.375p 252,552 0.47%
------------------- ------------------ ---------- -------------- ---------------
Lopes Gil 20,000 13.25p 8,020,000 14.84%
------------------- ------------------ ---------- -------------- ---------------
Marilyn Orcharton 20,000 13.445p 135,952 0.25%
------------------- ------------------ ---------- -------------- ---------------
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial
responsibilities / person closely associated
---- ----------------------------------------------------------
a) Names 1. Graham Hine
2. João Andrade
3. David Bridgland
4. Lopes Gil
5. Marilyn Orcharton
---- -------------------------- ------------------------------
2 Reason for the notification
---- ----------------------------------------------------------
a) Position/status Directors of the Company
---- -------------------------- ------------------------------
b) Initial notification Initial Notification
/Amendment
---- -------------------------- ------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
---- ----------------------------------------------------------
a) Name WideCells Group PLC
---- -------------------------- ------------------------------
b) LEI n/a
---- -------------------------- ------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
---- ----------------------------------------------------------
a) Description of Ordinary shares of 0.25 pence
the financial each
instrument, type
of instrument
---- -------------------------- ------------------------------
b) Identification GB00BD060S65
code
---- -------------------------- ------------------------------
c) Nature of the Purchase of Shares
transaction
---- -------------------------- ------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
------------- ----------
1. 13.37p 20,000
2. 13.25p 20,000
3. 13.375p 20,000
4. 13.25p 20,000
5. 13.445p 20,000
------------- ----------
---- -------------------------- ------------------------------
d) Aggregated information 100,000
- Aggregated volume 13.338p
- Price
------------------------------- ------------------------------
e) Date of the transaction 30 January 2017
---- -------------------------- ------------------------------
f) Place of the transaction London Stock Exchange
---- -------------------------- ------------------------------
Grant of Options
The 380,000 options will vest as follows (approximate):
-- 126,666 immediately;
-- 126,666 on 14 December 2017; and
-- 126,667 on 14 December 2018, subject to continuous
employment, except that they will vest automatically upon the sale
of the Company.
**ENDS**
For further information, please visit the Company's website
www.widecellsgroup.com, follow us on Twitter @WideCells_Group or
contact:
WideCells Group CEO - João Andrade Tel: +351 919
033 171
------------------- ------------------------- --------------
Vicarage Capital Broker - Jeremy Woodgate Tel: +44 (0)
Ltd & Rupert Williams 20 3651 2912
------------------- ------------------------- --------------
Shard Capital Broker - Damon Heath Tel: +44 (0)
Partners LLP & Erik Woolgar 207 186 9950
------------------- ------------------------- --------------
St Brides Partners PR - Elisabeth Cowell Tel: +44 (0)
Ltd & Charlotte Page 20 7236 1177
------------------- ------------------------- --------------
Notes to Editors
WideCells Group PLC is building an integrated stem cell services
company, focused on making stem cell treatments accessible and
affordable. The Directors believe that the use of cord blood stem
cells for transplant will drive one of the next important phases in
medicine and is therefore developing market leading products in
complementary, strategic areas which are designed to take advantage
of substantial market opportunities in one of the fastest growing
segments in the healthcare industry. With this in mind, it has
created three divisions:
-- CellPlan: the world's first stem cell healthcare insurance
plan with financial cover for medical treatment, travel and
accommodation expenses and concierge service to manage the
treatment process
-- WideCells: the Institute of Stem Cell Technology has been
established and is based in the University of Manchester Innovation
Center to focus on stem cell research and regenerative medicine.
WideCells also has international cryogenics divisions specialising
on stem cell storage.
-- WideAcademy: developing an education and training division to
promote awareness of the benefits of stem cell storage across the
global general practice community.
The Group has built an experienced senior management team that
has been integral to the development of its growth and business to
date.
Stem Cell Fast Facts:
-- Cord blood (which is taken from the umbilical cord) provides
the most effective source of stem cells for families due to it
being simple, safe and painless to collect relative to other
sources of stem cells such as bone marrow - WideCells will focus on
promoting the collection and storage of this.
-- Since 2005, there has been a 300% increase in the number of
illnesses that can be treated using stem cells
-- 82 illnesses can currently be treated using stem cell procedures
-- Despite initial storage often costing no more than a few
GBPthousand, actual treatment can cost in the GBPhundreds of
thousands
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014
(MAR).
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHWGUAAGUPMPUU
(END) Dow Jones Newswires
January 31, 2017 02:01 ET (07:01 GMT)
Iconic Labs (LSE:ICON)
Historical Stock Chart
From Apr 2024 to May 2024
Iconic Labs (LSE:ICON)
Historical Stock Chart
From May 2023 to May 2024